Safeguarding Women from Chemical Abortion Act

Diana Harshbarger

Republican · TN · Representative

Source: Congress.gov · FEC

• John W. Rose (R-TN-6)· 2026-03-18
• Mark Alford (R-MO-4)· 2026-03-20
• Neal P. Dunn (R-FL-2)· 2026-03-20
• Sheri Biggs (R-SC-3)· 2026-03-24
• Tracey Mann (R-KS-1)· 2026-03-24
• Christopher H. Smith (R-NJ-4)· 2026-04-22
• Mary E. Miller (R-IL-15)· 2026-05-14

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2026-03-12

Source: Congress.gov

This bill would revoke the FDA's approval of mifepristone, a medication used for medication abortion, and create a new federal lawsuit that would allow women to sue drug manufacturers for harm they claim resulted from using abortion medications. The measure would affect women seeking medication abortion, pharmaceutical companies that produce or distribute these drugs, and potentially expand legal liability in cases involving pregnancy complications.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 7902 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 7902 To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 12, 2026 Mrs. Harshbarger introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Safeguarding Women from Chemical Abortion Act''. SEC. 2. WITHDRAWAL OF APPROVAL OF THE DRUG MIFEPRISTONE FOR TERMINATION OF PREGNANCY. Effective upon the expiration of 14 days after the date of the enactment of this Act: (1) Approval of an application submitted under subsection (b) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for the drug mifepristone (marketed as Mifeprex, and also known as RU-486) with an indication for the termination of intrauterine pregnancy, and of any application submitted under subsection (j) of such section for a drug with the same indication and for which mifepristone is the reference drug, is deemed to have been withdrawn under subsection (e) of such section. (2) For purposes of sections 301(d) and 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d); 334), the introduction or delivery for introduction of a drug, the approval of which has been withdrawn as described in paragraph (1), into interstate commerce shall be considered a violation of section 505 of such Act (21 U.S.C. 355). (3) The drug mifepristone shall be considered misbranded for purposes of sections 301 and 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331; 334) if the drug bears labeling providing that the drug may be used for the termination of intrauterine pregnancy or that the drug may be used in conjunction with another drug for the termination of intrauterine pregnancy. SEC. 3. FEDERAL TORT FOR HARM TO WOMEN CAUSED BY CHEMICAL ABORTION DRUGS. (a) Definitions.--In this section: (1) Covered entity.--The term ``covered entity'' means a person that manufactures a covered medication for introduction into interstate commerce. (2) Covered medication.--The term ``covered medication'' means the drug mifepristone (marketed as Mifeprex, and also known as RU-486), with an indication for the termination of intrauterine pregnancy, approved pursuant to an application submitted under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355). (b) Liability.--A covered entity shall be liable in accordance with this section to any individual who suffers bodily injury or harm to mental health (including any physical, psychological, emotional, or physiological harm) that is attributable, in whole or in part, to the individual's use of a covered medication manufactured by a covered entity. (c)…

Private Right of Action.--An individual who suffers bodily injury or harm to mental health that is attributable, in whole or in part, to the individual's use of a covered medication as described in subsection (b) may bring a civil action against the covered entity in an appropriate district court of the United States or a State court of competent jurisdiction for-- (1) compensatory damages; (2) punitive damages; and (3) attorney's fees and costs. (d) Rules of Construction.--Nothing in this section shall be construed to preempt any State law that makes available any other remedy to an individual described in subsection (b). (e) Effective Date.--This section shall take effect on the date that is 90 days after the date of enactment of this Act. SEC. 4. RULE OF CONSTRUCTION. Nothing in this Act shall be construed to affect any provision of section 1461 of title 18, United States Code. <all>

• HR9743To amend title XXVII of the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to require group health plans and health insurance issuers offering group or individual health insurance coverage that provide benefits for sex-rejecting procedures to provide benefits for items and services to address the harms caused by sex-rejecting procedures and to restore healthy human form and functioning, to the greatest extent practicable.
  Referred to Committee · 2026-07-16
• HR9708SECURED Act of 2026
  Referred to Committee · 2026-07-15
• HR9613Nuclear Advisory Committee Reform Act
  Referred to Committee · 2026-07-14
• HR9389Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026
  Referred to Committee · 2026-06-25